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The therapeutic activity of daptomycin was compared with that of vancomycin in a rat model of subcutane-
ously implanted tissue cages chronically infected with strain Rev1, a spontaneous methicillin-susceptible
revertant of the methicillin-resistant Staphylococcus aureus strain MRGR3, showing equivalent virulence to
its parent. The MIC and MBC of daptomycin (in Mueller–Hinton broth supplemented with 50 mg/L Ca2+) or
vancomycin for strain Rev1 were 1–2 and 2–4 or 1 and 2 mg/L, respectively. In vitro elimination of strain Rev1
in the presence of 50% tissue cage fluid was more rapid with daptomycin 4 mg/L compared with vancomycin.
After 2 weeks of infection, viable counts of strain Rev1 averaged 6.49 log10 cfu/mL of tissue cage fluid (n = 87).
Intraperitoneal administration of daptomycin 30 mg/kg once daily, or vancomycin 50 mg/kg twice daily, pro-
duced antibiotic levels continuously above MBC. After 7 days of therapy with daptomycin or vancomycin,
mean ± S.E.M. counts of Rev1 decreased (P < 0.05) by 1.11 ± 0.25 (n = 28) or 0.80 ± 0.31 (n = 35) log10 cfu/mL,
respectively, compared with cages of untreated animals, but were not significantly different from each other.
In daptomycin-treated rats, three cages yielded subpopulations with reduced susceptibility to daptomycin.
In conclusion, a low dose regimen of daptomycin was at least equivalent to vancomycin against chronic
foreign body infections due to S. aureus. Drug dosage should be adapted to obtain inflammatory fluid levels
of daptomycin minimizing emergence of resistant subpopulations.
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Introduction
Prosthetic device infections, in particular those resulting from
Staphylococcus aureus, are notoriously difficult to treat, and micro-
bial eradication frequently requires the removal of infected materials.
Recent clinical studies using combinations of fluoroquinolones and
rifampicin yielded promising results for the treatment of orthopaedic
prosthetic S. aureus infections without prosthesis removal.1–4 Unfor-
tunately, a vast majority of methicillin-resistant strains of S. aureus
(MRSA) are also resistant to virtually all fluoroquinolones,5 which
severely limits the therapeutic armentarium for the treatment of
foreign body infections. Thus, glycopeptide therapy with vanco-
mycin or teicoplanin, alone or in combination with rifampicin,6–8
frequently remains the only available therapy for severe MRSA
infections, but does not always prevent the emergence of rifampicin-
resistant mutants.9 An additional concern is the recent discovery of
glycopeptide-intermediate or -resistant strains of S. aureus in several
parts of the world.10–14 The increasing use of glycopeptides for
therapy of Gram-positive infections may further promote the emer-
gence of more highly glycopeptide-resistant strains.15,16
Daptomycin is a lipopeptide antibiotic with potent in vitro bacteri-
cidal activity against a wide range of Gram-positive pathogens,
including antibiotic-resistant staphylococci.17–20 The mechanism of
action of daptomycin is not fully understood, but seems to be distinct
from that of major cell wall-active agents, such as β-lactams and
glycopeptides. Daptomycin binds in a calcium-dependent manner to
Gram-positive cytoplasmic membranes,21,22 and disrupts membrane
function, dissipating membrane potential and inhibiting macro-
molecular biosynthesis. Daptomycin is uniformly potent against
S. aureus clinical isolates in large surveillance studies.23–27 The in
vivo activity of daptomycin is currently being evaluated in both
therapeutic trials and experimental models.19,28 Optimization of dapto-
mycin pharmacokinetics and pharmacodynamics against severe
S. aureus infections17,28–32 requires maximum efficacy and safety, and
the maintenance of bactericidal levels in deep-seated compart-
ments.17,19,33
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We previously showed the usefulness of a rat tissue cage model
of S. aureus chronic foreign body infections for evaluating various
categories of antimicrobial agents such as vancomycin,34 teico-
planin,35 imipenem,36 and several fluoroquinolones including fler-
oxacin,34 sparfloxacin, temafloxacin, ciprofloxacin,37 levofloxacin
and trovafloxacin,38 alone or in combination with rifampicin.34,35,39
In this study, we evaluate the efficacy of a once-daily dosing of
daptomycin compared with a twice-a-day regimen of vancomycin in




Strain Rev1 is a spontaneous methicillin-susceptible revertant of MRSA
strain MRGR3, a clinical isolate from a patient with catheter-related
sepsis. Strain Rev1 was found to be as virulent in the rat model of chronic
S. aureus tissue cage infection as its MRSA parental strain.34,37,39 Except
for the loss of the methicillin resistance element, strain Rev1 exhibits an
antibiotic resistance pattern identical to its MRSA parent, including
resistance to penicillin, gentamicin, chloramphenicol, erythromycin,
tetracycline and polymyxin B, but susceptibility to clindamycin, rifam-
picin and all fluoroquinolones.34,37,39
Antimicrobial agents
For in vitro studies, daptomycin (Cubist Pharmaceutical, Inc., Lexing-
ton, MA, USA) was solubilized in distilled water at a concentration of
1 mg/mL and further diluted in saline. For in vivo studies, daptomycin
was solubilized in saline at a concentration of 7.5 mg/mL. Commercially
available vancomycin hydrochloride (Lilly, Giessen, Germany) was
suspended as recommended by the manufacturer.
In vitro studies
MICs of daptomycin and vancomycin for strain Rev1 were determined in
cation-adjusted Mueller–Hinton broth (CAMHB) containing 20–25 mg/L
Ca2+ and 10–12.5 mg/L Mg2+ by the standard broth macrodilution
method, with an average inoculum of 106 cfu/mL, as described by the
NCCLS.41 For daptomycin MIC, CAMHB was supplemented with
additional calcium to a physiological concentration of 50 mg/L Ca2+
(CSMHB).
To screen for the possible carryover effects of each antibiotic during
the MBC determinations, 100 µL portions were taken from all tubes with
no visible growth. These were subcultured, either undiluted or diluted
10-fold in saline, on Mueller–Hinton agar (MHA) for 36 h at 37°C. The
MBC was defined as the lowest concentration that killed 99.9% of the
original inoculum.
Killing kinetic studies
Portions of 100 µL containing 106 cfu of strain Rev1 (obtained from
exponential-phase cultures) were added to sterile plastic tubes of 1 mL of
either CSMHB or CAMHB that included either daptomycin or vanco-
mycin (4 mg/L), respectively, in a shaking waterbath at 37°C. The
number of viable organisms was determined by subculturing 50 µL of
10-fold diluted portions on MHA after 0, 1, 3, 6 and 24 h of incubation.
Colonies were enumerated with a laser colony counter (Spiral System)
after 48 h of incubation at 37°C. The detection limit was 2 log10 cfu/mL.
No significant carryover of antibiotics was observed by using these
experimental conditions. To evaluate the impact of tissue cage fluid
proteins on the bactericidal activity of daptomycin 4 mg/L, the rate of
elimination of strain Rev1 from tubes containing 1 mL of a mixture of
CSMHB and sterile tissue cage fluid (pooled from 20 different cages
of uninfected animals) in a 1:1 ratio was also recorded.
To evaluate the susceptibility to daptomycin or vancomycin of strain
Rev1 recovered from infected tissue cage fluids, the bacteria were iso-
lated from the tissue cage fluids by centrifugation, and were treated with
0.1% Triton X-100 and sonication to disrupt the host cells, as described
previously.35 This procedure is used to reduce bacterial clumping, and
was shown repeatedly to be harmless for ex vivo bacteria regarding their
ability to multiply and their susceptibility to antibiotics.35,42 Thereafter,
tissue cage bacteria were exposed to either daptomycin or vancomycin
(4 mg/L each) in tubes containing 1 mL of either CSMHB or CAMHB,
respectively, supplemented with 50% pooled tissue cage fluid, and their
rate of elimination was compared with that of strain Rev1 grown in vitro.
To make the comparison with ex vivo bacteria more relevant, bacteria
grown in vitro were taken from saline-washed cultures of stationary
phase organisms.35,38 The number of viable organisms after 0, 2, 4, 6 and
24 h of incubation was determined, as described above. For each group,
the reductions in cfu counts from time zero to further times of incubation
were expressed as ∆log10 cfu/mL. The means ± S.E.M. of the ∆log10
cfu/mL of three independent determinations were analysed for signifi-
cant differences by unpaired t-tests. Data were considered significant
when P < 0.05 using two-tailed significance levels.
Treatment of chronic tissue cage infections
Experiments involving rats were approved by the Ethics Committee of
the Faculty of Medicine, University of Geneva, and by the Veterinary
Office of the State of Geneva. Four tissue cages were implanted sub-
cutaneously, as described previously,34 in Wistar rats that had been
anaesthetized with an intraperitoneal injection of a mixture of ketamine
(90 mg/kg) and xylazine (5 mg/kg). At 3 weeks post-implantation, tissue
cage fluid was aspirated and checked for sterility. To establish a chronic
S. aureus infection, tissue cages were inoculated with 0.1 mL of saline
containing 0.2 × 106 to 2 × 106 cfu of a log-phase culture of strain Rev1.
Two weeks later, all tissue cages containing more than 105 cfu/mL of
fluid were included in the therapeutic protocols.
Rats infected with strain Rev1 were randomized to receive (by the
intraperitoneal route for 7 days) either a once-a-day regimen of dapto-
mycin (30 mg/kg) or a twice-a-day regimen of vancomycin (50 mg/kg),
or were left untreated.
At 12 h after the last injection of vancomycin or 24 h after the last
injection of daptomycin, quantitative cultures of 10-fold serially diluted
tissue cage fluids were performed on MHA. To optimize the yield of
viable bacteria, tissue cage fluids were sonicated briefly (60 W, 1 min) to
disrupt the biofilm and phagocytic cells before the serial dilutions and
plating. Plates were incubated for 24–48 h at 37°C. The detection limit
was 2 log10 cfu/mL of tissue cage fluid. The differences in cfu counts
between days 1 and 8 were determined and expressed as ∆log10 cfu/mL.
For each treatment group, results were expressed as means ± S.E.M. Com-
parison of bacterial counts in the different groups was performed by one-
way analysis of variance and t-tests corrected for multiple groups. Data
were considered significant when P <0.05 using two-tailed significance
levels.
Resistance to antimicrobial agents
In initial experiments, the bacteria recovered from cage fluids on day 8 of
therapy were screened for the emergence of resistance to daptomycin on
MHA. Samples (of 100 µL) of 10-fold-diluted cage fluid were plated
onto MHA containing daptomycin 4 mg/L. Plates were incubated for
48 h at 37°C. The detection limit was 1 log10 cfu/mL of tissue cage fluid.
Further analysis of subpopulations that grew on the daptomycin-
containing agar from some tissue cages was first performed on colonies
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recovered from the primary antibiotic-containing plates. The identifica-
tion of representative individual colonies as S. aureus was assessed by
standard microbiological procedures, and their clonal relationship with
strain Rev1 confirmed by pulse-field gel electrophoresis (PFGE). The
overall antimicrobial susceptibility of 10 colonies isolated from each
primary daptomycin-containing plate was compared with strain Rev1 by
disc diffusion using MHA, according to NCCLS recommendations. The
antibiotics tested were daptomycin (30 µg paper discs provided by
Cubist) and 15 commercially available discs containing penicillin,
oxacillin, gentamicin, norfloxacin, ciprofloxacin, trovafloxacin, clinda-
mycin, erythromycin, fusidic acid, co-trimoxazole, fosfomycin, rifam-
picin, vancomycin, teicoplanin or mupirocin. Three additional colonies
from each daptomycin-containing plate were tested separately for
increased daptomycin MICs, compared with strain Rev1, by a standard
broth microdilution test, as recommended by NCCLS, using either
CAMHB or CSMBH.41 Finally, the stability of the daptomycin MICs
was checked by agar dilution, broth microdilution and macrodilution
assays performed on individual colonies that had been stored in skim
milk for 6–12 months at –70°C.
Pharmacokinetics of antimicrobial agents
The pharmacokinetic properties of vancomycin in rat tissue cage fluid
have been estimated previously.34 In rats treated with daptomycin, its
pharmacokinetic levels in tissue cage fluids were determined at various
time intervals (0, 2, 4, 6, 12 and 24 h) on days 4 and 7 of therapy. Simi-
larly, blood levels of rats treated with daptomycin were also determined
at various time intervals (0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h) after single-
dose intraperitoneal administration of the antimicrobial agent. The blood
was collected by cardiac puncture into heparinized tubes. Plasma was
collected by centrifugation and samples were stored at –20°C until analy-
sis.
Daptomycin analytical assay
Daptomycin was detected using an internal standard of ethylparaben, and
was isolated by protein precipitation with methanol, followed by HPLC.
The mobile phase consisted of 90% mobile phase A (acetonitrile: 0.5%
NH4H2PO4 34:66, v/v) and 10% mobile phase B (acetonitrile: 0.5%
NH4H2PO4 20:80, v/v) at a flow rate of 1.5 mL/min. Serum drug concen-
trations were determined by reverse-phase HPLC using a Metachem
Hypersil C8 analytical column and a Waters Xterra RP18 guard column
(ANSYS Technologies, Inc., Lake Forest, CA, USA). At a flow rate of
1.5 mL/min, daptomycin shows a retention time of 14–16 min. Samples
were analysed at 214 nm. The detection of daptomycin concentrations
in rat plasma was linear across the range of 7.5–400 mg/L. This method
has been validated for daptomycin over the concentration range of
3–500 mg/L, with a lower limit of quantification equal to the lowest
calibration level of 3 mg/L.
The concentrations of daptomycin in rat tissue cage fluid were esti-
mated by a previously described microbiological assay,43 except for the
use of Antibiotic medium 11 and Sarcina lutea as the test strain. To avoid
a potential bias due to protein binding, all tissue cage fluids were diluted
with one volume of PBS. Thus, tissue cage fluid protein concentrations of
samples were equivalent to those of daptomycin standards prepared in
PBS supplemented with 50% of sterile pooled tissue cage fluid. Under
these experimental conditions, the limit of detection of the daptomycin
assay was 1 mg/L.
The areas under the concentration–time curve (AUC) of daptomycin
in either plasma or tissue cage fluid were estimated by the linear trapezoi-




The MIC and MBC of daptomycin in CSMHB were 1–2 and 2–4 mg/L,
respectively, for strain Rev1; the MIC and MBC of daptomycin in
the presence of 50% tissue cage fluid added to CSMHB were 2 and
4 mg/L, respectively, for strain Rev1; the MIC and MBC of vanco-
mycin in CAMHB were 1 and 2 mg/L, respectively, for strain Rev1.
Time–kill studies performed in CSMHB showed rapid elimin-
ation of exponential-phase cultures of strain Rev1 by daptomycin
4 mg/L. The reduction in the viable counts of strain Rev1 by dapto-
mycin exceeded 3 log10 cfu/mL after 3 h (data not shown). A similar
reduction in the viable counts of strain Rev1 by daptomycin 4 mg/L
was observed in CSMHB supplemented with 50% tissue cage fluid
(data not shown).
Pharmacokinetics of antimicrobial agents in tissue cage fluid
At day 4 of therapy, the mean levels of daptomycin in tissue cage
fluids (n = 6) of animals treated with daptomycin were 5.4 at time
zero, 6.6 at 2 h, 9.8 at 4 h, 11.8 at 6 h, 10.0 at 12 h and 3.4 mg/L at 24 h,
respectively, after administration of a 30 mg/kg once-daily regimen
(Figure 1). Similar concentrations of daptomycin were recorded at
day 7 of therapy (data not shown). Since residual levels of dapto-
mycin were nearly equivalent to the MBC of this antimicrobial agent
for strain Rev1, recorded in CSMHB containing 50% tissue cage
fluid, the daptomycin once-daily regimen yielded bactericidal levels
of daptomycin in infected tissue cage fluids throughout therapy. At
day 4 of therapy, the tissue cage fluid AUC0–24 of daptomycin was
195.8 mg⋅h/L.
In comparison, blood levels of animals treated with a 30 mg/kg
intraperitoneal regimen of daptomycin showed a Cmax of 141 mg/L at
1 h, and a concentration of 8.2 mg/L at 8 h. The trough level was 0,
which differs from human pharmacokinetics in which daptomycin
maintains trough levels of 1–9 mg/L. The AUC0–24 of daptomycin
was 558 mg⋅h/L, which is only slightly higher than the clinical
AUC0–24 of 468 mg⋅h/L.44
Figure 1. Pharmacokinetic levels of daptomycin in plasma, and tissue cage
fluids of rats on day 4 of therapy with 30 mg/kg once-daily dosing.
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The average peak and trough tissue cage fluid levels of vanco-
mycin determined in a previous study34 were 12 and 2 mg/L at 4 and
12 h, respectively.
Treatment of chronic tissue cage infections
At the onset of therapy, average bacterial counts for cages infected
with strain Rev1 were 6.87 ± 0.28 cfu/mL for controls (n = 24), 6.25 ±
0.17 log10 cfu/mL for animals receiving daptomycin once a day
(n = 28), and 6.43 ± 0.13 log10 cfu/mL for animals receiving vanco-
mycin twice a day (n = 35). At the end of the 7 day treatment period,
bacterial counts in the tissue cages of control animals showed a slight
and non-significant increase of 0.24 ± 0.23 log10 cfu/mL (n = 24). In
contrast, both the daptomycin and vancomycin regimens (Figure 2)
led to significant reductions in bacterial counts in tissue cage fluids of
1.11 ± 0.25 (n = 28; P = 0.001) and 0.80 ± 0.31 log10 cfu/mL (n = 35;
P = 0.02), respectively, compared with tissue cage fluids of control
animals. The higher average reduction in cfu counts of rats treated
with daptomycin compared with that of vancomycin-treated animals
did not reach statistical significance (P = 0.45).
Comparison of daptomycin activity on bacteria grown in vitro 
and in vivo
To evaluate the bactericidal activity of daptomycin compared with
vancomycin against tissue cage fluid organisms of strain Rev1 in
conditions relevant to therapy, we assayed, in parallel, the elimin-
ation rates of tissue cage and in vitro grown bacteria by 4 mg/L of
either antimicrobial agent in the presence of 50% sterile tissue cage
fluid in CSMHB. Stationary-phase were preferred to log-phase
organisms to make the comparison with ex vivo bacteria more
relevant.35,38 Figure 3 shows a significantly (P < 0.001) higher elimin-
ation rate of stationary-phase organisms by daptomycin 4 mg/L,
compared with vancomycin, during the initial 4 h period of drug
exposure, which led to >3 log10 reductions in viable counts at 4 versus
6 h, respectively. However, the most impressive differences in the
bactericidal activities of daptomycin compared with vancomycin
were seen with bacteria freshly removed from infected cages. During
the initial 6 h period of drug exposure, the average reductions in
viable counts of tissue cage bacteria by daptomycin 4 mg/L were 2.1
and 2.6 log10 cfu/mL at 4 and 6 h, respectively, compared with 0.3 and
0.6 log10 cfu/mL with vancomycin 4 mg/L (Figure 3). The presence
of 50% tissue cage fluid, yielding average protein concentrations of
10–15 mg per mL of CSMHB, did not significantly impair the bac-
tericidal activity of daptomycin against bacteria grown in vitro or in
vivo. Since tissue cage fluid was uniformly present in all assay con-
ditions, this protein supplement was therefore not responsible for the
markedly different elimination of tissue cage bacteria by daptomycin
compared with vancomycin.
Screening of antibiotic resistance during daptomycin therapy
After exclusion of six cages that contained undetectable numbers
of bacteria (2 log10 cfu/mL), daptomycin resistance was screened
in 22 cage fluids by direct plating of post-therapy tissue cage bacteria
on MHA containing daptomycin 4 mg/L. This low concentration of
daptomycin, equivalent to its MBC for strain Rev1 in the presence of
tissue cage fluid, was selective enough to prevent bacterial growth
of post-therapy isolates in 19 of 22 cages of daptomycin-treated
animals, whose average viable counts at day 8 were 5.05 ± 0.25
log10 cfu/mL. In contrast, three of the 22 cages whose average
viable counts (6.86 ± 0.13 log10 cfu/mL) at day 8 were relatively
high, yielded bacterial subpopulations on daptomycin-supplemented
MHA with an average frequency of 2.2 × 10–4. The number of
colonies that grew on daptomycin-supplemented MHA from these
three cages were 6, 23 and 31 cfu, respectively, yielding an average
concentration of 3.21 ± 0.21 log10 cfu/mL. Phenotypical properties
(haemolysis, coagulase) and the PFGE pattern of the bacteria grown
on daptomycin-supplemented MHA were identical to those of the
parental strain Rev1. Further studies of daptomycin resistance
phenotypes were performed with the two cages yielding the highest
Figure 2. Decrease in viable counts of S. aureus Rev1 in tissue cage fluids of rats
treated with the different regimens for 7 days. DAP, rats treated with daptomycin
30 mg/kg once a day; VAN, rats treated with vancomycin 50 mg/kg twice a day. n,
number of evaluated cages in each group.
Figure 3. Comparison of daptomycin bactericidal activity on S. aureus Rev1,
either grown in MHB as stationary phase cultures (in vitro), or recovered from
pooled, chronically infected tissue cages (ex vivo). Incubation with either dapto-
mycin (DAP; 4 mg/L) or vancomycin (VAN; 4 mg/L) was carried out in a 1:1 mix-
ture of MHB and sterile tissue cages fluids pooled from 20 different uninfected
cages implanted in rats.
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viable counts (>20 cfu per plate) of daptomycin-supplemented
MHA.
The stability and homogeneity of the daptomycin resistance
phenotypes were evaluated on 10 colonies randomly selected from
each daptomycin-supplemented primary plate. We compared their
overall antimicrobial susceptibility with that of strain Rev1, using
disc diffusion on MHA. Each daptomycin-selected colony exhibited
a consistent 3–4 mm reduction in zone sizes around the daptomycin
discs (19–20 mm) compared with those recorded around the parental
strain Rev1 (23 mm). In contrast, all other zone sizes around 15
additional antibiotic discs were identical for all daptomycin-selected
colonies and Rev1, which further confirmed their respective clonal
identity.
The resistance phenotypes of six daptomycin-selected colonies
were found to be stable after 1 year of storage at –70°C, since the viable
counts of all subclones on MHA supplemented with daptomycin 4
mg/L were nearly equivalent to those enumerated on antibiotic-free
MHA. In contrast, the cfu counts of strain Rev1 plated on the same
daptomycin-containing MHA medium represented only 10–8 of those
on daptomycin-free MHA, thus confirming the low spontaneous
emergence of daptomycin resistance in the parental strain.
When tested by the broth microdilution or macrodilution methods
in CAMHB adjusted to 50 mg/L Ca2+ or non-adjusted, daptomycin-
selected colonies showed average 4-fold and 8-fold increases in
daptomycin MICs, respectively, compared with strain Rev1. Similar
values were found after 1 year of storage at –70°C, or after repeated
passages in daptomycin-free MHB (data not shown).
Discussion
Establishment of an optimal dosing of daptomycin for the safe and
effective treatment of serious Gram-positive infections, in particular
those resistant to multiple antibiotics, would represent an important
therapeutic achievement. The rapid in vitro bactericidal activity of
daptomycin, combined with its low potential for in vitro spontaneous
acquisition of antibiotic resistance21 and absence of cross-resistance
with other antimicrobial agents, represent attractive properties for
targeting microbial organisms involved in chronic or foreign body
infections. Many of the early animal studies conducted in the 1980s
and early 1990s indeed showed daptomycin’s efficacy in deep-seated
infections, such as endocarditis,29,31,32 but did not define optimal
pharmacokinetic and pharmacodynamic properties for this antibiotic
that might be of direct use for currently performed human trials.
Another frequently mentioned problem associated with daptomycin
in vitro testing is the requirement of well-characterized microbiologi-
cal media, with well-adjusted contents of ionized calcium, to obtain
reliable in vitro data on daptomycin susceptibility or resistance in
staphylococci and enterococci.17–27 The lack of properly labelled
information on the cation content on a number of commercially avail-
able liquid and solid media might be the source of significant errors in
susceptibility testing of staphylococcal and enterococcal clinical
isolates.
A useful property of subcutaneous tissue cage models of implant-
associated infections due to S. aureus34–37,39 or Staphylococcus
epidermidis 45,46 is the possibility of the direct assessment of the levels
of each antimicrobial agent in tissue cage fluids. This allows direct
estimates to be made of the tissue cage concentration–time profile of
each antimicrobial agent in tissue cage fluids. In recent years,
pharmacodynamic modelling of the therapeutic efficacies of anti-
microbial agents has been developed, and is a powerful tool that
combines the pharmacokinetic properties of each agent with the anti-
microbial susceptibilities of their microbial targets.47,48 These
pharmacodynamic concepts were applied recently to daptomycin in a
murine thigh model of S. aureus infection, which indicated that the
plasma AUC/MIC ratio was an important predictor of successful
microbiological outcome.28 The plasma AUC0–24 of daptomycin
recorded in our tissue cage rat model (which was slightly higher than
the average AUC0–24 of human volunteers receiving a clinical dose of
4 mg/kg)44 falls within the AUC0–24 values leading to bactericidal
activities in the murine thigh S. aureus infection model.28 Despite
being 65% lower than that recorded in rat plasma, the tissue cage fluid
AUC0–24 of daptomycin was still sufficient to exert a significant bac-
tericidal effect in the locally infected cage fluids, even against strain
Rev1. The efficacy of daptomycin, compared with that of several
other antimicrobial agents tested in the hard-to-treat rat model of
chronic foreign body infection,34–39 was at least equivalent to a larger
daily regimen of vancomycin, and is an indication for its good bac-
tericidal activity in vivo. This assumption was confirmed by in vitro
testing demonstrating bactericidal activity of daptomycin at 4 mg/L,
equivalent to its MBC against strain Rev1. Daptomycin is ∼90%
bound by serum proteins.44 However, in vitro testing indicated that
the presence of tissue cage fluid components, which contain serum-
derived proteins, did not significantly affect the bactericidal activity
of daptomycin at a concentration of 4 mg/L against organisms, col-
lected from either a stationary-phase culture or even freshly removed
from infected cage fluids.
Tissue cage grown bacteria frequently express in vivo-induced
tolerance to different antibiotics.34,35,42 This in vivo-induced toler-
ance, which is either not expressed or rapidly disappears under in
vitro conditions, is referred to as phenotypical tolerance.49 In contrast
to the previously described high level of phenotypical tolerance
expressed by tissue cage bacteria against teicoplanin,35 daptomycin
still demonstrates a high level of bactericidal activity against the
potentially tolerant bacteria.
Since the relatively low concentrations of daptomycin reached in
the chronically infected cage fluids, varying only from the MBC to
three times the MBC levels, already showed therapeutic efficacy, these
data suggest that optimization of the pharmacokinetic and pharmaco-
dynamic parameters to this particular infection model potentially
might lead to significantly improved therapeutic responses by reach-
ing higher local levels of daptomycin, as suggested by a recent pre-
liminary report.50
The emergence, in three infected cages, of subpopulations exhib-
iting decreased susceptibility to daptomycin, compared with the
parental strain Rev1, was an interesting microbiological finding
whose real clinical significance is still uncertain. A single previous
study mentioned the emergence of S. aureus subpopulations exhibit-
ing diminished susceptibility during daptomycin therapy of experi-
mental endocarditis in rabbits.31 These rabbits were treated with
suboptimal dosages of daptomycin, which yielded isolates with an
increase in MIC value in 13% of rabbits. Trough levels of dapto-
mycin in tissue cage fluid were just equivalent to the MBC for strain
Rev1. Animal-to-animal variability cannot exclude that daptomycin
levels fell below the MBC in these three rats, allowing emergence of
resistant subpopulations.
In conclusion, daptomycin showed an encouraging in vivo effi-
cacy in the rat model of chronic foreign body infections due to
S. aureus Rev1, and was equivalent to that of vancomycin. Dapto-
mycin produced significant reductions in the bacterial burden of
S. aureus. High tissue levels of daptomycin seem to be required to
minimize emergence of subpopulations exhibiting decreased suscep-
tibility to daptomycin. Prediction of the therapeutic efficacies of var-
P. Vaudaux et al.
94
ious antibiotics against foreign body infections may be difficult by
relying exclusively on in vitro pharmacodynamic models derived
from pharmacokinetic data in the plasma compartment. Our data
further emphasize the value of performing experiments in animals for
the primary evaluation of new therapeutic agents.
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